S E Holden1,2, S Jenkins-Jones2, C Ll Morgan2, J R Peters3, G Schernthaner4, C J Currie1,2. 1. The Institute of Population Medicine, School of Medicine, Cardiff University, Cardiff, UK. 2. Global Epidemiology, Pharmatelligence, Cardiff, UK. 3. Department of Medicine, University Hospital of Wales, Cardiff, UK. 4. Department of Medicine, Rudolfstiftung Hospital Vienna, Vienna, Austria.
Abstract
AIMS: To characterize the prevalence of Type 2 diabetes between 1991 and 2013 in the UK and to determine whether corresponding glucose control and survival had changed in the diabetic population during this period. METHODS: For this retrospective cohort study, people diagnosed with Type 2 diabetes between 1991 and 2013 were identified from the Clinical Practice Research Datalink (CPRD) and the annual point prevalence calculated. Mean HbA1c by year was estimated. The Cox proportional hazards model was used to calculate the risk of all-cause mortality by year for incident cases of Type 2 diabetes treated with glucose-lowering therapy. RESULTS: Crude prevalence of diagnosed Type 2 diabetes increased from 1.32% [95% confidence interval (95% CI) 1.30% to 1.34%] in 1991 to 4.54% (4.52% to 4.56%) in 2013. Mean HbA1c for people with diagnosed Type 2 diabetes was 71 mmol/mol (8.6%) in 1991, 59 mmol/mol (7.5%) in 2003 and 58 mmol/mol (7.5%) in 2013. For diagnosed Type 2 diabetes treated with glucose-lowering therapy, when compared with 1991, the hazard ratio for all-cause mortality was 0.33 (0.27-0.41) in 2013. CONCLUSION: The prevalence of diagnosed Type 2 diabetes trebled in the UK between 1991 and 2013. Improved survival in people with diagnosed Type 2 diabetes is likely to account, at least in part, for the increase in prevalence observed.
AIMS: To characterize the prevalence of Type 2 diabetes between 1991 and 2013 in the UK and to determine whether corresponding glucose control and survival had changed in the diabetic population during this period. METHODS: For this retrospective cohort study, people diagnosed with Type 2 diabetes between 1991 and 2013 were identified from the Clinical Practice Research Datalink (CPRD) and the annual point prevalence calculated. Mean HbA1c by year was estimated. The Cox proportional hazards model was used to calculate the risk of all-cause mortality by year for incident cases of Type 2 diabetes treated with glucose-lowering therapy. RESULTS: Crude prevalence of diagnosed Type 2 diabetes increased from 1.32% [95% confidence interval (95% CI) 1.30% to 1.34%] in 1991 to 4.54% (4.52% to 4.56%) in 2013. Mean HbA1c for people with diagnosed Type 2 diabetes was 71 mmol/mol (8.6%) in 1991, 59 mmol/mol (7.5%) in 2003 and 58 mmol/mol (7.5%) in 2013. For diagnosed Type 2 diabetes treated with glucose-lowering therapy, when compared with 1991, the hazard ratio for all-cause mortality was 0.33 (0.27-0.41) in 2013. CONCLUSION: The prevalence of diagnosed Type 2 diabetes trebled in the UK between 1991 and 2013. Improved survival in people with diagnosed Type 2 diabetes is likely to account, at least in part, for the increase in prevalence observed.
Authors: Nanna Lindekilde; Giesje Nefs; Jan Erik Henriksen; Mathias Lasgaard; Miranda Schram; Katrine Rubin; Femke Rutters; Mika Kivimaki; Frans Pouwer Journal: BMJ Open Date: 2019-05-30 Impact factor: 2.692
Authors: Katherine N Bachmann; Christianne L Roumie; Andrew D Wiese; Carlos G Grijalva; John B Buse; Robert Bradford; Emily O Zalimeni; Patricia Knoepp; Sofia Dard; Heather L Morris; William T Donahoo; Nada Fanous; Vivian Fonseca; Bonnie Katalenich; Sujung Choi; Darcy Louzao; Emily O'Brien; Megan M Cook; Russell L Rothman; Rosette J Chakkalakal Journal: Pharmacol Res Perspect Date: 2020-10